Advertisement

Topics

Intersect ENT to Report First Quarter 2018 Financial Results

16:19 EDT 16 Apr 2018 | Businesswire

Intersect ENT, Inc.

Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 1, 2018. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET that same day.

To access the conference call via the internet, go to the "Investor Relations" page of the company's web site at www.intersectENT.com. To access the live conference call via phone, dial 1-844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 1-412-317-5205. Participants may expedite telephone access by pre-registering for the call using the following link: http://dpregister.com/10118921.

A replay of the conference call may be accessed that same day after 8:00 p.m. ET at www.intersectENT.com or via phone at 1-877-344-7529, or 1-412-317-0088 for international callers. The reference number to enter the replay of the call is 10118921. The dial-in replay will be available for a week after the call and via the internet for approximately one month.

About Intersect ENT®

Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.

XENT-F

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com

NEXT ARTICLE

More From BioPortfolio on "Intersect ENT to Report First Quarter 2018 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement